Paul Boyce
Pulmonary Disease · Atlanta, GANPI 1912988445
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.1%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 34.2% of the total. Reporting peaked in 2024 at $4,091 and has fallen 56.5% since, to $1,779 in 2025.
Across 271 payments — averaging $43.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$4K
- Sanofi Pasteur Inc.$2K
- GSK$791
- AstraZeneca$678
- United Therapeutics Corporation$469
- Electromed, Inc.$330
- plus $3K from 32 others
Across 62 payments — averaging $6351.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$186K
- Janssen Research & Development, LLC$126K
- Karyopharm Therapeutics Inc.$52K
- Genentech, Inc.$29K
- Actelion Pharmaceuticals, Ltd$90
What the payments were for
- Consulting fees$2,72523%
- Speaking & faculty fees$2,46921%
- Travel & lodging$420%
- Food & beverage$6,52955%
- Education$911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 39 | $4,053 |
| Sanofi Pasteur Inc. | 2 | $2,469 |
| GSK | 47 | $791 |
| AstraZeneca | 27 | $678 |
| United Therapeutics Corporation | 12 | $469 |
| Electromed, Inc. | 25 | $330 |
| Merck | 12 | $328 |
| Amgen(2 entities) | 13 | $292 |
| Grifols USA, LLC | 11 | $252 |
| Bayer | 9 | $211 |
| Regeneron Healthcare Solutions, Inc. | 8 | $195 |
| Inari Medical, Inc. | 2 | $191 |
| Verona Pharma, Inc. | 6 | $178 |
| Edwards Lifesciences | 1 | $153 |
| Boehringer Ingelheim | 6 | $125 |
| Insmed, Inc. | 4 | $124 |
| Sanofi | 4 | $117 |
| Mylan Specialty L.p. | 5 | $102 |
| Philips North America LLC | 5 | $99 |
| Baxter Healthcare | 3 | $92 |
| ANI Pharmaceuticals, Inc. | 4 | $88 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $65 |
| Johnson & Johnson(2 entities) | 2 | $50 |
| AbbVie | 2 | $49 |
| Paratek Pharmaceuticals, Inc. | 2 | $43 |
| Viatris Specialty LLC | 2 | $40 |
| Pfizer | 2 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Inogen, Inc. | 2 | $32 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Shire North American Group Inc | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Circassia Inc. | 1 | $19 |
| Phadia US Inc. | 1 | $19 |
| Chiesi USA, Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Sandoz | 1 | $15 |
| Gilead | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$3,000
- OPSUMIT$3,000
- TYVASO$244
- FASENRA$234
- FLOWTRIEVER CATHETER, S$177
- CT THROMBECTOMY SYSTEM KIT$177
- FloTrac Sensor$153
- ORENITRAM$119
How this compares
$11,856 in reported general payments places this provider in the 75th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 161 | $114,956 |
| Tadalafil | 25 | $16,512 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $12,251 |
| EliquisApixaban | 16 | $10,472 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $9,970 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $8,285 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $6,905 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 17 | $2,300 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $1,770 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 80 | $1,663 |
| Wixela InhubFluticasone Propion/Salmeterol | 16 | $1,481 |
| Cefdinir | 17 | $381 |
| Prednisone | 47 | $186 |
| Potassium Chloride | 11 | $175 |
| Methylprednisolone | 21 | $124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $791 | $137,177199 claims |
| PfizerEliquis | $39 | $10,47216 claims |
| AstraZenecaSymbicort | $678 | $6,90521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Atlanta
- Colin SwensonAtlanta$255K
- Eric FlenaughAtlanta$93K
- Gregory MartinAtlanta$88K
- Victor TsengAtlanta$55K
- Ralitza MartinAtlanta$48K
- Venkatesh LakshminarayananAtlanta$33K
- Sisir AkkineniAtlanta$21K
- Gerald StatonAtlanta$21K
- Mirza AliAtlanta$16K
- Srihari VeeraraghavanAtlanta$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.